Exploring antibody repurposing for COVID-19: beyond presumed roles of therapeutic antibodies
Abstract The urgent need for a treatment of COVID-19 has left researchers with limited choice of either developing an effective vaccine or identifying approved/investigational drugs developed for other medical conditions for potential repurposing, thus bypassing long clinical trials. In this work, w...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2021-05-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-021-89621-6 |
| _version_ | 1818839576058265600 |
|---|---|
| author | Puneet Rawat Divya Sharma Ambuj Srivastava Vani Janakiraman M. Michael Gromiha |
| author_facet | Puneet Rawat Divya Sharma Ambuj Srivastava Vani Janakiraman M. Michael Gromiha |
| author_sort | Puneet Rawat |
| collection | DOAJ |
| description | Abstract The urgent need for a treatment of COVID-19 has left researchers with limited choice of either developing an effective vaccine or identifying approved/investigational drugs developed for other medical conditions for potential repurposing, thus bypassing long clinical trials. In this work, we compared the sequences of experimentally verified SARS-CoV-2 neutralizing antibodies and sequentially/structurally similar commercialized therapeutic monoclonal antibodies. We have identified three therapeutic antibodies, Tremelimumab, Ipilimumab and Afasevikumab. Interestingly, these antibodies target CTLA4 and IL17A, levels of which have been shown to be elevated during severe SARS-CoV-2 infection. The candidate antibodies were evaluated further for epitope restriction, interaction energy and interaction surface to gauge their repurposability to tackle SARS-CoV-2 infection. Our work provides candidate antibody scaffolds with dual activities of plausible viral neutralization and immunosuppression. Further, these candidate antibodies can also be explored in diagnostic test kits for SARS-CoV-2 infection. We opine that this in silico workflow to screen and analyze antibodies for repurposing would have widespread applications. |
| first_indexed | 2024-12-19T03:56:29Z |
| format | Article |
| id | doaj.art-91d1b92f687040aebb2d043b3dfc7e60 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-12-19T03:56:29Z |
| publishDate | 2021-05-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-91d1b92f687040aebb2d043b3dfc7e602022-12-21T20:36:48ZengNature PortfolioScientific Reports2045-23222021-05-0111111110.1038/s41598-021-89621-6Exploring antibody repurposing for COVID-19: beyond presumed roles of therapeutic antibodiesPuneet Rawat0Divya Sharma1Ambuj Srivastava2Vani Janakiraman3M. Michael Gromiha4Protein Bioinformatics Laboratory, Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology MadrasProtein Bioinformatics Laboratory, Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology MadrasProtein Bioinformatics Laboratory, Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology MadrasInfection Biology Lab, Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology MadrasProtein Bioinformatics Laboratory, Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology MadrasAbstract The urgent need for a treatment of COVID-19 has left researchers with limited choice of either developing an effective vaccine or identifying approved/investigational drugs developed for other medical conditions for potential repurposing, thus bypassing long clinical trials. In this work, we compared the sequences of experimentally verified SARS-CoV-2 neutralizing antibodies and sequentially/structurally similar commercialized therapeutic monoclonal antibodies. We have identified three therapeutic antibodies, Tremelimumab, Ipilimumab and Afasevikumab. Interestingly, these antibodies target CTLA4 and IL17A, levels of which have been shown to be elevated during severe SARS-CoV-2 infection. The candidate antibodies were evaluated further for epitope restriction, interaction energy and interaction surface to gauge their repurposability to tackle SARS-CoV-2 infection. Our work provides candidate antibody scaffolds with dual activities of plausible viral neutralization and immunosuppression. Further, these candidate antibodies can also be explored in diagnostic test kits for SARS-CoV-2 infection. We opine that this in silico workflow to screen and analyze antibodies for repurposing would have widespread applications.https://doi.org/10.1038/s41598-021-89621-6 |
| spellingShingle | Puneet Rawat Divya Sharma Ambuj Srivastava Vani Janakiraman M. Michael Gromiha Exploring antibody repurposing for COVID-19: beyond presumed roles of therapeutic antibodies Scientific Reports |
| title | Exploring antibody repurposing for COVID-19: beyond presumed roles of therapeutic antibodies |
| title_full | Exploring antibody repurposing for COVID-19: beyond presumed roles of therapeutic antibodies |
| title_fullStr | Exploring antibody repurposing for COVID-19: beyond presumed roles of therapeutic antibodies |
| title_full_unstemmed | Exploring antibody repurposing for COVID-19: beyond presumed roles of therapeutic antibodies |
| title_short | Exploring antibody repurposing for COVID-19: beyond presumed roles of therapeutic antibodies |
| title_sort | exploring antibody repurposing for covid 19 beyond presumed roles of therapeutic antibodies |
| url | https://doi.org/10.1038/s41598-021-89621-6 |
| work_keys_str_mv | AT puneetrawat exploringantibodyrepurposingforcovid19beyondpresumedrolesoftherapeuticantibodies AT divyasharma exploringantibodyrepurposingforcovid19beyondpresumedrolesoftherapeuticantibodies AT ambujsrivastava exploringantibodyrepurposingforcovid19beyondpresumedrolesoftherapeuticantibodies AT vanijanakiraman exploringantibodyrepurposingforcovid19beyondpresumedrolesoftherapeuticantibodies AT mmichaelgromiha exploringantibodyrepurposingforcovid19beyondpresumedrolesoftherapeuticantibodies |